Skip to main content
All lobbying filings

Crossroads Strategies, LLC

Crossroads Strategies, LLC filed a Q3 report for Vertex Pharmaceuticals Incorporated on October 17, 2026, reporting $50,000 in lobbying income.

Lobbying for Vertex Pharmaceuticals Incorporated · biopharmaceutical company

As filed: CROSSROADS STRATEGIES, LLC for VERTEX PHARMACEUTICALS INCORPORATED.

All filings by Crossroads Strategies, LLC · Everything Vertex Pharmaceuticals Incorporated has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 17, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Health Issues

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

Medical/Disease Research/Clinical Labs

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.

Medicare/Medicaid

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

Trade (domestic/foreign)

Policies impacting the manufacturing pharmaceutical products including tariffs.

 Bills named in this filing 2

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem